Researchers created an AI tool that predicts recurrence of Barrett’s esophagus following endoscopic eradication therapies with greater than 90% accuracy.
Key Details
- 1AI model predicts recurrence of Barrett’s esophagus and related dysplasia or cancer after EET.
- 2Model achieved over 90% accuracy using data from more than 2,500 patients.
- 3Key risk factors: longer affected tissue length, higher body weight, older age, more treatment sessions, higher-grade dysplasia.
- 4Recurrence occurred in about 30% of patients, with average return two years after therapy.
- 5Validated on internal and external datasets, showing robust performance across groups.
- 6International collaborations underway to further validate AI tool.
Why It Matters
This AI model could enable risk-stratified, personalized surveillance for Barrett’s esophagus after therapy, improving early cancer detection and reducing unnecessary procedures. If widely validated, the tool may optimize healthcare resource use and patient outcomes in endoscopic GI imaging workflows.
Source
EurekAlert
Related News
•EurekAlert
AI Pathology Tool SÉMIL Improves Stage II Bowel Cancer Risk Assessment
A La Trobe University-developed AI tool accurately predicts relapse risk in stage II bowel cancer using digital pathology images and descriptions.
•EurekAlert
AI Tool Predicts Which Rectal Cancer Patients Benefit from Intensive Therapy
UCL researchers developed an AI that analyzes biopsy slides to identify rectal cancer patients who benefit from adding irinotecan to standard chemoradiotherapy.
•EurekAlert
AI-Guided Handheld Cardiac Ultrasound Reduces Referrals and Costs in Spain
AI-guided handheld cardiac ultrasound enables primary care physicians to detect heart failure, reducing specialist referrals and saving costs.